Home > Neurology > AAN 2022 > Epilepsy > Fenfluramine: possible new treatment for Lennox-Gastaut syndrome

Fenfluramine: possible new treatment for Lennox-Gastaut syndrome

Presented By
Dr Kelly Knupp, Children's Hospital Colorado, CO, USA
Conference
AAN 2022
Doi
https://doi.org/10.55788/57f51d14
Fenfluramine was associated with a sustained reduction in frequency of seizures resulting in drops for up to a year in patients with Lennox-Gastaut syndrome (LGS) in the open-label extension (OLE) of a phase 3 study. The novel treatment was generally well tolerated. Fenfluramine (3-trifluoromethyl-N-ethylamphetamine) is a substituted amphetamine that is structurally similar to serotonin. It is thought to reduce seizures by acting as an agonist of specific serotonin receptors in the brain, including 5-HT1D, 5-HT2A, and 5-HT2C. Fenfluramine is used to treat seizures in patients with Dravet syndrome [1]. At the AAN 2022 meeting, an interim analysis of long-term safety and efficacy of fenfluramine in patients with LGS was presented. Dr Kelly Knupp (Children's Hospital Colorado, CO, USA) shared the results of the OLE (NCT03355209) of the randomised-controlled,...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on